KALA BIO, Inc.
KALA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001479419
No open-market purchases or sales by KALA BIO, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $1.21M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in KALA BIO, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 29
- +4 vs. Q4 2023
- Shares held
- 616.8K
- +90.9K (+17.3%) vs. Q4 2023
- Total value
- $4.88M
- +$1.20M (+32.7%) vs. Q4 2023
- New holders
- 4
- 5 more added
- Sold out
- 0
- 9 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KALA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 15 | $1.21M |
| Q1 2026 | 30 | $294.0K |
| Q4 2025 | 32 | $1.58M |
| Q3 2025 | 24 | $2.69M |
| Q2 2025 | 30 | $17.3M |
| Q1 2025 | 29 | $23.7M |
| Q4 2024 | 33 | $24.0M |
| Q3 2024 | 27 | $12.1M |
| Q2 2024 | 29 | $14.8M |
| Q1 2024 | 29 | $4.88M |
| Q4 2023 | 25 | $3.68M |
| Q3 2023 | 26 | $4.57M |
| Q2 2023 | 30 | $5.56M |
| Q1 2023 | 26 | $4.81M |
| Q4 2022 | 30 | $12.8M |
| Q3 2022 | 56 | $1.36M |
| Q2 2022 | 70 | $2.27M |
| Q1 2022 | 88 | $33.7M |
| Q4 2021 | 85 | $30.9M |
| Q3 2021 | 108 | $79.5M |
| Q2 2021 | 107 | $171.3M |
| Q1 2021 | 118 | $248.9M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding KALA BIO, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 23 | $0 | 0.00% | −40−63.5% | Reduced |
| Parallel Advisors, LLC | 1 | $8 | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 3 | $24 | 0.00% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 3 | $24 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 18 | $143 | 0.00% | +1+5.9% | Added |
| The PNC Financial Services Group, Inc. | 20 | $159 | 0.00% | +20 | New |
| Old Point Trust & Financial Services N A | 20 | $159 | 0.00% | +20 | New |
| JPMorgan Chase & Co | 35 | $274 | 0.00% | +4+12.9% | Added |
| Bank of America Corp | 111 | $885 | 0.00% | −2,476−95.7% | Reduced |
| Steward Partners Investment Advisory, LLC | 120 | $956 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 241 | $1.92K | 0.00% | 00.0% | Unchanged |
| CWM, LLC | 200 | $2.00K | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 296 | $2.32K | 0.00% | 00.0% | Unchanged |
| Compagnie Lombard Odier SCmA | 400 | $3.14K | 0.00% | 00.0% | Unchanged |
| Banque Cantonale Vaudoise | 808 | $6.00K | 0.00% | 00.0% | Unchanged |
| Covestor Ltd | 1,048 | $8.00K | 0.01% | −214−17.0% | Reduced |
| Morgan Stanley | 1,361 | $10.8K | 0.00% | −260−16.0% | Reduced |
| Tower Research Capital LLC (TRC) | 1,621 | $12.9K | 0.00% | −2,736−62.8% | Reduced |
| UBS Group AG | 2,175 | $17.3K | 0.00% | +1,479+212.5% | Added |
| Knights of Columbus Asset Advisors LLC | 2,417 | $19.3K | 0.00% | −2,417−50.0% | Reduced |
| Renaissance Technologies LLC | 11,400 | $91.0K | 0.00% | −2,700−19.1% | Reduced |
| Citadel Advisors LLC | 13,468 | $105.6K | 0.00% | +13,468 | New |
| Geode Capital Management, LLC | 18,153 | $142.4K | 0.00% | −312−1.7% | Reduced |
| Board of Trustees of The Leland Stanford Junior University | 21,127 | $168.4K | 0.01% | 00.0% | Unchanged |
| BlackRock Inc. | 27,177 | $216.6K | 0.00% | −144−0.5% | Reduced |
| Vanguard Group Inc | 41,981 | $334.6K | 0.00% | +13,946+49.7% | Added |
| UBS Oconnor LLC | 72,554 | $568.8K | 0.02% | +72,554 | New |
| Millennium Management LLC | 133,403 | $1.05M | 0.00% | +729+0.5% | Added |
| Baker Bros. Advisors LP | 266,613 | $2.12M | 0.03% | 00.0% | Unchanged |